42 unknown. 42 Phase 2, 12 Phase 3, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 42 | Unknown 42 |
| Phase 3 | 12 | Unknown 12 |
| Phase 1 | 7 | Unknown 7 |
Follow Anemia, Hemolytic: new trials by email Literature Review of Anemia, Hemolytic trials Research Report on Anemia, Hemolytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis Lidocaine Iv, Placebo - Sickle Cell Disease, Sickle Cell Crisis | Phase 2 | Unknown | Community Medical Center, Toms River, NJ | 100 | 2024-01-01 | 2023-08-29 |
| SMILES: Study of Montelukast in Sickle Cell Disease Montelukast, Oral Placebo - Anemia, Sickle Cell, Sleep-Disordered Breathing | Phase 2 / Phase 3 | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 200 | 2023-10-16 | 2023-11-01 |
| The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia Zanubrutinib - Refractory/Relapsed Autoimmune Hemolytic Anemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 33 | 2023-09-01 | 2023-11-29 |
| Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease - Sickle Cell Disease | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 30 | 2023-03-22 | 2023-09-21 |
| Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP) Sirolimus 0.5 mg - Beta-Thalassemia | Phase 2 | Unknown | Università degli Studi di Ferrara | 45 | 2021-04-13 | 2021-11-12 |
| The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia Ibrutinib - Refractory/Relapsed Autoimmune Hemolytic Anemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2020-05-01 | 2024-09-25 |
| Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients Acacia Senegal extract, Pectin - Sickle Cell Anemia in Children | Phase 2 / Phase 3 | Unknown | Al-Neelain University | 100 | 2020-02-15 | 2020-01-28 |
| TAPS2 Transfusion Antenatally in Pregnant Women With SCD Serial prophylactic exchange blood transfusion (SPEBT). - Sickle Cell Disease, Pregnancy, High Risk | Phase 2 | Unknown | Guy's and St Thomas' NHS Foundation Trust | 50 | 2019-05-02 | 2019-08-02 |
| Outcomes Mandate National Integration With Cannabis as Medicine Cannabis, Medical, RYAH-Medtech Inhaler - Chronic Pain, Chronic Pain Syndrome | Phase 2 | Unknown | OMNI Medical Services, LLC | 200000 | 2018-12-01 | 2022-06-02 |
| the Efficacy and Safety of Sugammadex in Children 0-2 Years Old Sugammadex - Anesthesia, Pediatric Cancer | Phase 2 / Phase 3 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 62 | 2018-11-15 | 2018-11-02 |
| Rifaximin to Modify the Disease Course in Sickle Cell Disease Rifaximin - Sickle Cell Disease, Antibiotics | Phase 2 | Unknown | New York Medical College | 20 | 2018-08-22 | 2019-03-14 |
| Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial Influenza vaccine - Preventing Stroke in Sickle Cell Anaemia | Phase 2 / Phase 3 | Unknown | Makerere University | 150 | 2018-08-22 | 2018-09-12 |
| Central Nervous System Vascular Changes in Adult Sickle Cell Disease and the Effect of Treatment With Simvastatin Simvastatin 40mg - Sickle Cell Disease, Stroke | Phase 1 / Phase 2 | Unknown | University of Campinas, Brazil | 28 | 2018-03-05 | 2020-10-12 |
| A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD Memantine Hydrochloride - Sickle Cell Disease | Phase 2 | Unknown | HaEmek Medical Center, Israel | 40 | 2018-02-02 | 2019-11-01 |
| Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified Autologous CD34+ cells genetically modified - Beta Thalassemia Major | Phase 1 / Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 10 | 2017-09-15 | 2017-09-08 |
| The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan Hydroxyurea - Thalassemia, Beta | Phase 2 | Unknown | Dr.Saqib Hussain Ansari | 100 | 2017-08-21 | 2017-09-20 |
| The Effective and Safety of Thalidomide in TI Thalidomide - Thalassemia | Phase 2 | Unknown | Xiao-Lin Yin | 100 | 2017-05-02 | 2017-06-14 |
| Dose-Finding Study of SC411 in Children With Sickle Cell Disease Docosahexaenoic Acid, Placebo - Sickle Cell Disease | Phase 2 | Unknown | Micelle BioPharma Inc | 68 | 2017-03-02 | 2019-01-31 |
| Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis Hydroxyurea - Anemia, Sickle Cell, Anemia; Sickle-Cell, With Crisis | Phase 2 | Unknown | Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti | 30 | 2016-11-01 | 2017-02-23 |
| The Effective and Safety of Thalidomide in NTDT Thalidomide - Thalassemia | Phase 2 | Unknown | Xiao-Lin Yin | 30 | 2016-09-01 | 2017-03-22 |
Showing 20 of 42. Sign in to see all of them.
Anemia, Sickle Cell (22) · beta-Thalassemia (13) · Thalassemia (5) · Anemia (3) · Anemia, Aplastic (3) · Anemia, Hemolytic, Autoimmune (3) · Bone Marrow Failure Disorders (3) · Hematologic Diseases (3) · Thrombosis (3) · Acquired Immunodeficiency Syndrome (2) · Chronic Pain (2) · Hemoglobinuria (2) · Hemoglobinuria, Paroxysmal (2) · Hemolysis (2)
Hemic and Lymphatic Diseases (42) · Anemia (39) · Hematologic Diseases (39) · Anemia, Hemolytic, Congenital (36) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (36) · Genetic Diseases, Inborn (36) · Hemoglobinopathies (34) · Pathological Conditions, Signs and Symptoms (11) · Thalassemia (11) · Pathologic Processes (6) · Signs and Symptoms (6) · Cardiovascular Diseases (5) · Immune System Diseases (5) · Urogenital Diseases (5)
Deferiprone (3) · Hydroxyurea (3) · Levamisole (3) · fludarabine phosphate (3) · Alemtuzumab (2) · Busulfan (2) · Cyclosporine (2) · Deferasirox (2) · Deferoxamine (2) · Docosahexaenoic Acids (2) · Glucocorticoids (2) · Isoflurophate (2) · Melphalan (2) · Sirolimus (2) · Thalidomide (2)
Ain Shams University (5) · Institute of Hematology & Blood Diseases Hospital, China (5) · Xiao-Lin Yin (2) · Al-Neelain University (1) · Assistance Publique - Hôpitaux de Paris (1) · Columbia University (1) · Community Medical Center, Toms River, NJ (1) · Diane George (1) · Dr.Saqib Hussain Ansari (1) · Faculdade Adventista da Bahia (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Federal University of Bahia (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Guy's and St Thomas' NHS Foundation Trust (1) · HaEmek Medical Center, Israel (1)
China (8) · United States (8) · Egypt (5) · Brazil (3) · United Kingdom (3) · Iran (2) · Italy (2) · Canada (1) · France (1) · Israel (1) · Nigeria (1) · Pakistan (1) · Russia (1) · Saudi Arabia (1) · Sudan (1)
Yin X Lin, director (2) · A O Dosunmu, M.D. (1) · Alessandro Aiuti, MD, PhD (1) · Anna Konstantinova, MD (1) · Ariel Koren, Professor (1) · Behjat Moayedi, Professor (1) · Bruno Benites, MD (1) · David Barth, MD (1) · Diane George, MD (1) · Dr. Ryan O Lakin, MD JD (1) · Eugene Oteng-Ntim (1) · Fabio Ciceri, MD (1) · Fenella Kirkham, Dr (1)
PMID 29931453, PMID 22875626, PMID 23927461, PMID 24797180, PMID 25600572, PMID 26021713, PMID 29119631, PMID 29548623, PMID 29788942, PMID 30097463, PMID 32312326, PMID 34629091, PMID 37975597, PMID 38775255, PMID 38954844, PMID 41603130
2014 (1), 2018 (1)